MET and non-small cell lung carcinoma: In solid tumors, only one antibody, amivantamab, that targets EGFR and MET, has received regulatory approval for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations [14,15].